Jan 8 (Reuters) - AMAG Pharmaceuticals Inc:
* AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE
* SEES Q4 2017 REVENUE $156 MILLION TO $163 MILLION * SEES FY 2017 REVENUE $613 MILLION TO $620 MILLION * SEES FY 2017 REVENUE UP 15 PERCENT * SEES Q4 2017 REVENUE UP ABOUT 5 PERCENT * - ‍FOR Q4 OF 2017, AMAG EXPECTS AN OPERATING LOSS OF BETWEEN $6 MILLION AND $16 MILLION​
* - ‍EXPECTS 2017 TOTAL GAAP REVENUE TO BE BETWEEN $607 MILLION AND $614 MILLION​
* SEES ‍ 2017 OPERATING LOSS OF BETWEEN $292 MILLION AND $302 MILLION (DUE PRIMARILY TO A Q3 NON-CASH ACCOUNTING CHARGE)​
* SEES ‍2018 TOTAL GAAP REVENUE $500 MILLION - $560 MILLION​
* SEES ‍2018 GAAP OPERATING LOSS $147 MILLION - $117 MILLION​
* Q4 REVENUE VIEW $161.1 MILLION -- THOMSON REUTERS I/B/E/S
* FY2017 REVENUE VIEW $616.0 MILLION -- THOMSON REUTERS I/B/E/S
* FY2018 REVENUE VIEW $504.1 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:
 